NASDAQ:ESPR Esperion Therapeutics (ESPR) Stock Price, News & Analysis $2.13 +0.03 (+1.43%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Esperion Therapeutics Stock (NASDAQ:ESPR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Esperion Therapeutics alerts:Sign Up Key Stats Today's Range$2.12▼$2.2650-Day Range$1.61▼$2.1652-Week Range$0.77▼$3.40Volume3.36 million shsAverage Volume6.21 million shsMarket Capitalization$403.55 millionP/E RatioN/ADividend YieldN/APrice Target$8.17Consensus RatingHold Company OverviewEsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Esperion Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks86th Percentile Overall ScoreESPR MarketRank™: Esperion Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 206th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingEsperion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageEsperion Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Esperion Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.04) to $0.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Esperion Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted18.23% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Esperion Therapeutics has recently decreased by 5.55%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-2.76 Percentage of Shares Shorted18.23% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Esperion Therapeutics has recently decreased by 5.55%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News Sentiment0.81 News SentimentEsperion Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Esperion Therapeutics this week, compared to 3 articles on an average week.Search Interest28 people have searched for ESPR on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows7 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $227.00 in company stock.Percentage Held by InsidersOnly 1.00% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Esperion Therapeutics' insider trading history. Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Stock News HeadlinesEsperion Therapeutics (NASDAQ:ESPR) Lifted to Buy at StockNews.comOctober 29 at 2:09 AM | americanbankingnews.comBank of America Securities Keeps Their Sell Rating on Esperion (ESPR)October 28 at 10:36 PM | markets.businessinsider.comTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…October 29, 2024 | Timothy Sykes (Ad)Esperion to Report Third Quarter 2024 Financial Results on November 7October 24, 2024 | globenewswire.comMillennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc HoldingsOctober 17, 2024 | finance.yahoo.comEsperion Therapeutics (NASDAQ:ESPR) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comEsperion Therapeutics (NASDAQ:ESPR) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comEsperion shares reiterate Buy rating on trial dataOctober 5, 2024 | uk.investing.comSee More Headlines ESPR Stock Analysis - Frequently Asked Questions How have ESPR shares performed this year? Esperion Therapeutics' stock was trading at $2.99 at the beginning of 2024. Since then, ESPR stock has decreased by 28.8% and is now trading at $2.13. View the best growth stocks for 2024 here. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings results on Monday, August, 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.10. The biopharmaceutical company had revenue of $73.83 million for the quarter, compared to analysts' expectations of $51.90 million. Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' top institutional investors include SG Americas Securities LLC (0.04%), Boomfish Wealth Group LLC (0.02%) and Traphagen Investment Advisors LLC (0.01%). Insiders that own company stock include Sheldon L Koenig, Eric Warren, Joanne M Foody, Benjamin Looker and J Martin Carroll. View institutional ownership trends. How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Esperion Therapeutics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Marinus Pharmaceuticals (MRNS) and AUO (AUOTY). Company Calendar Last Earnings8/12/2024Today10/29/2024Next Earnings (Confirmed)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ESPR CUSIPN/A CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees240Year FoundedN/APrice Target and Rating Average Stock Price Target$8.17 High Stock Price Target$16.00 Low Stock Price Target$2.50 Potential Upside/Downside+283.4%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,250,000.00 Net Margins-35.46% Pretax Margin-35.46% Return on EquityN/A Return on Assets-15.71% Debt Debt-to-Equity RatioN/A Current Ratio1.97 Quick Ratio1.49 Sales & Book Value Annual Sales$277.79 million Price / Sales1.45 Cash FlowN/A Price / Cash FlowN/A Book Value($3.85) per share Price / Book-0.55Miscellaneous Outstanding Shares189,460,000Free Float194,263,000Market Cap$403.55 million OptionableOptionable Beta1.00 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:ESPR) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.